Characteristics of responders and non-responders to Tezepelumab in a complex, real-world severe asthma population

<bold>Introduction</bold>: In the current era of asthma biologic therapies, severe asthmatics are achieving significant control over exacerbations and oral corticosteroid (OCS) exposure. Tezepelumb, offers a novel mechanism of inhibition of thymic stromal lymphopoietin, with subsequent broad type II biomarker reduction. What eludes clinicians is an understanding of characteristics that predict a more favourable response to Tezepelumab in the real-world setting. <bold>Methods:</bold> A retrospective review of adult patients who commenced Tezepelumab 210mg s/c 4 weekly was completed. All patients had ERS/ATS defined severe asthma and had either failed to respond to prior asthma biologics or were ineligible to commence any other available biologic therapies. <bold>Results:</bold> There were 51 patients (35% male and 65% female) with a mean age of 55. 84% were on maintenance OCS with a median dose of 15mg (IQR 10-20mg). 36 patients (71%) responded to Tezepelumab; defined as a reduction in OCS by 50% at 6 months. Of note, 61% had failed to respond to 1 or more asthma biologics previously. Table 1 compares the characteristics of responders with non-responders. <bold>Conclusions:</bold> Whilst there was a statistically significant response to Tezepelumab in this real-world setting, there were no clear demographic or clinical characteristics that were predictive of a more favourable response to it, which clearly identifies an area for further study. <fig><object-id>erj;64/suppl_68/PA1201/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>